RenBiologics Assets Brochure
-
Fully Human Antibody Library
-
Preclinical PCC and Clinical Assets
-
Antibody Assets Licensing & Co-Development
Biocytogen’s fully human antibody library is comprised of 400K+ sequences targeting 900+ antigens, applicable to multiple therapeutic areas. These antibodies were generated using proprietary RenMice® strains, each engineered to lack a certain drug target gene. This fully human, hyperimmune, target-specific (HiTS) platform increases the likelihood that our antibodies have desirable characteristics, including:
- Lower risk of immunogenicity
- Cross-species recognition to facilitate preclinical efficacy and safety evaluation
- High specificity, affinity and diversity, owing to the comprehensive coverage of immunoglobulin variable region genes in our RenMice models
- Feasibility of assembly into various modalities, including bispecific antibodies (bsAbs)/engagers, bispecific ADCs (bsADCs), nanobodies and TCR-mimic antibodies for your novel therapeutic application
- Facilitates discovery for a comprehensive list of popular yet difficult drug targets, including cell membrane proteins, extracellular proteins, and intracellular proteins.
